Resource Summary Report

Generated by NIF on Sep 17, 2026

IMR-5

RRID:CVCL_1306
Type: Cell Line

Proper Citation

RRID:CVCL_1306

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1306

Proper Citation: RRID:CVCL_1306

Description: Cell line IMR-5 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Neuroblastoma

Defining Citation: PMID:6160155, PMID:12536080, PMID:15150091, PMID:16822308, PMID:18724359, PMID:20164919, PMID:23202128, PMID:24466371, PMID:27397505, PMID:28350380, PMID:30894373, PMID:31581737, PMID:35839778

Comments: Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: IMR-5

Synonyms: IMR 5, IMR5, IMR-05, Institute for Medical Research-5

Cross References: BTO:BTO_0005846, CLO:CLO_0006950, EFO:EFO_0022692, CLDB:cl5097, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-3610, cancercelllines:CVCL_1306, Cell_Model_Passport:SIDM01206, ChEMBL-Cells:CHEMBL3308201, ChEMBL-Targets:CHEMBL2366209, Cosmic:907170, Cosmic:1019939, Cosmic:1109364, Cosmic:1161989, Cosmic:1167417, Cosmic:1890113, Cosmic-CLP:907170, DepMap:ACH-002248, EGA:EGAS00001000978, GDSC:907170, GEO:GSM1669935, GEO:GSM2371236, GEO:GSM2394389, IARC_TP53:21396, ICLC:HTL00009, LINCS_LDP:LCL-1984, PharmacoDB:IMR5_660_2019,

PRIDE:PXD030304, PubChem_Cell_line:CVCL_1306, Wikidata:Q54897648

ID: CVCL_1306

Hierarchy: cvcl_0346

Record Creation Time: 20220427T220634+0000

Record Last Update: 20260913T004602+0000

Ratings and Alerts

No rating or validation information has been found for IMR-5.

No alerts have been found for IMR-5.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Bajgain P, et al. (2026) Engineering functionality-optimized fully human B7-H3 CAR T cells for enhanced solid tumor therapy. Cell reports. Medicine, 7(5), 102782.

Hollander JF, et al. (2025) Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with Neuroblastoma. Cancer research communications, 5(1), 167.

Papadopoulos D, et al. (2024) The MYCN oncoprotein is an RNA-binding accessory factor of the nuclear exosome targeting complex. Molecular cell, 84(11), 2070.

Lee JY, et al. (2023) Identification and targeting of protein tyrosine kinase 7 (PTK7) as an immunotherapy candidate for neuroblastoma. Cell reports. Medicine, 4(6), 101091.

Papadopoulos D, et al. (2022) MYCN recruits the nuclear exosome complex to RNA polymerase II to prevent transcription-replication conflicts. Molecular cell, 82(1), 159.

Buongervino S, et al. (2021) Antibody-Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization. Molecular cancer therapeutics, 20(11), 2228.

Shim J, et al. (2020) YAP-Mediated Repression of HRK Regulates Tumor Growth, Therapy Response, and Survival Under Tumor Environmental Stress in Neuroblastoma. Cancer research, 80(21), 4741.

Cossa G, et al. (2020) Localized Inhibition of Protein Phosphatase 1 by NUAK1 Promotes Spliceosome Activity and Reveals a MYC-Sensitive Feedback Control of Transcription. Molecular cell, 77(6), 1322.